Drug approvalRSSToday
EU panel recommends expanded use of DMD treatment Agamree
A European health committee has recommended that Agamree, a medicine for Duchenne muscular dystrophy (DMD), be approved for use in younger children starting at age 2. Previously, the drug was approved for older children and adults. This recommendation means more DMD patients in Europe could potentially access this treatment if the European Medicines Agency approves the committee's suggestion.
WHY IT MATTERSThis expanded approval could allow children with DMD as young as age 2 to start Agamree treatment earlier, potentially slowing muscle weakness progression during critical early development years.